Takeda's motesanib misses in Asian trial
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it will terminate the Phase III MONET-A trial of motesanib diphosphate ( AMG 706) to treat stage IV or recurrent non-small cell lung cancer (NSCLC) after the candidate plus carboplatin and paclitaxel missed the trial's primary endpoint of increasing progression-free survival (PFS). The study evaluated patients in Japan, South Korea, Taiwan and Hong Kong.
In 2011, motesanib plus the same chemotherapies failed to increase overall survival (OS) vs. placebo in the U.S. Phase III MONET1 trial. Takeda said a pre-planned subgroup analysis of MONET1 data showed that the small molecule antagonist of VEGF receptors 1, 2 and 3, platelet derived growth factor receptor ( PDGFR) and c-Kit led to "significant and consistent findings" in Asian patients. ...